 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
5 News |  |
- | PAT-SM6 / Patrys
Journal: Cell Surface GRP78 as a Death Receptor and an Anticancer Drug Target. (Pubmed Central) - Nov 29, 2019
As csGRP78 is found to mainly configur as an external peripheral protein on cancer cell surface, how it can transmit death signals to the cytoplasmic environment remains enigmatic. With the recent encouraging results from the natural csGRP78 targeting pro-apoptotic monoclonal antibody PAT-SM6 in early-stage cancer clinical trials, the potential to develop a novel class of anticancer therapeutics targeting csGRP78 is becoming more compelling.
- | PAT-SM6 / Patrys
Trial completion: Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2014
P1, N=12, Completed, Sponsor: Patrys Ltd.
With the recent encouraging results from the natural csGRP78 targeting pro-apoptotic monoclonal antibody PAT-SM6 in early-stage cancer clinical trials, the potential to develop a novel class of anticancer therapeutics targeting csGRP78 is becoming more compelling. Recruiting --> Completed
- | PAT-SM6 / Patrys
New P1 trial: Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 14, 2012
P1, N=12, Completed, Sponsor: Patrys Ltd.